Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
Status:
Withdrawn
Trial end date:
2034-08-19
Target enrollment:
Participant gender:
Summary
The main object of this multicenter, randomized, double-blind, placebo-controlled phase III
trial is to assess impact of maintenance of orteronel on disease progression and hence on
quality of life of patients with metastatic castration resistant prostate cancer pretreated
with novel hormonal agents who have non-progressive disease after chemotherapy with a taxane.